×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RCUS – arcus biosciences, inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RCUS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/12
05:02 pm
rcus
Arcus Biosciences (NYSE:RCUS) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating.
Medium
Report
Arcus Biosciences (NYSE:RCUS) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating.
1/10
01:07 am
rcus
Arcus Biosciences (NYSE:RCUS) was downgraded by analysts at Wall Street
Low
Report
Arcus Biosciences (NYSE:RCUS) was downgraded by analysts at Wall Street
1/8
07:09 am
rcus
Arcus Biosciences (NYSE:RCUS) was given a new $20.00 price target on by analysts at Morgan Stanley.
Medium
Report
Arcus Biosciences (NYSE:RCUS) was given a new $20.00 price target on by analysts at Morgan Stanley.
1/7
04:23 pm
rcus
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs [Yahoo! Finance]
Medium
Report
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs [Yahoo! Finance]
1/7
04:05 pm
rcus
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs
Medium
Report
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs
12/18
04:05 pm
rcus
Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference
12/17
11:29 am
rcus
This Growth Stock With 137% Upside Faces New Challenge: Buy, Hold or Sell? [Yahoo! Finance]
Low
Report
This Growth Stock With 137% Upside Faces New Challenge: Buy, Hold or Sell? [Yahoo! Finance]
12/17
09:08 am
rcus
Arcus Biosciences: Casdatifan Takes Center Stage After STAR-221 [Seeking Alpha]
Low
Report
Arcus Biosciences: Casdatifan Takes Center Stage After STAR-221 [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/9
04:26 pm
rcus
Form 4 Arcus Biosciences, Inc. For: Jan 08 Filed by: ROSEN TERRY J
Low
Report
Form 4 Arcus Biosciences, Inc. For: Jan 08 Filed by: ROSEN TERRY J
1/8
01:28 pm
rcus
Form SCHEDULE 13G/A Arcus Biosciences, Inc. Filed by: BlackRock, Inc.
Neutral
Report
Form SCHEDULE 13G/A Arcus Biosciences, Inc. Filed by: BlackRock, Inc.
1/7
04:16 pm
rcus
Form 4 Arcus Biosciences, Inc. For: Jan 05 Filed by: Jaen Juan C.
Medium
Report
Form 4 Arcus Biosciences, Inc. For: Jan 05 Filed by: Jaen Juan C.
1/5
04:58 pm
rcus
Form 144 Arcus Biosciences, Inc. Filed by: Jaen Juan C.
Low
Report
Form 144 Arcus Biosciences, Inc. Filed by: Jaen Juan C.
1/2
04:19 pm
rcus
Form 4 Arcus Biosciences, Inc. For: Dec 31 Filed by: Goeltz II Robert C.
Medium
Report
Form 4 Arcus Biosciences, Inc. For: Dec 31 Filed by: Goeltz II Robert C.
1/2
04:19 pm
rcus
Form 4 Arcus Biosciences, Inc. For: Dec 30 Filed by: ROSEN TERRY J
Medium
Report
Form 4 Arcus Biosciences, Inc. For: Dec 30 Filed by: ROSEN TERRY J
12/31
06:26 pm
rcus
Form 144 Arcus Biosciences, Inc. Filed by: Goeltz II Robert C.
Low
Report
Form 144 Arcus Biosciences, Inc. Filed by: Goeltz II Robert C.
12/18
05:36 pm
rcus
Form 4 Arcus Biosciences, Inc. For: Dec 16 Filed by: Tang Carolyn C.
Low
Report
Form 4 Arcus Biosciences, Inc. For: Dec 16 Filed by: Tang Carolyn C.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/26
Arcus Biosciences Inc (NYSE: RCUS) is now covered by analysts at Mizuho. They set a "buy" rating on the stock.
15.6%
2/18 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. 12.7%
8/8 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 11.0%
3/4 Arcus Biosciences Inc (NYSE: RCUS) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $24.00 price target on the stock. 7.7%
6/11 Arcus Biosciences to Provide a Mid-Year Update on Clinical and Preclinical Programs 6.4%
11/12 Arcus Biosciences Inc (NYSE: RCUS) is now covered by analysts at SunTrust Banks, Inc.. They set a "buy" rating on the stock. 5.4%
4/9 Arcus Biosciences Announces New Employment Inducement Grants 5.3%
12/18 Arcus Biosciences, in Collaboration with Genentech, Announces Two Randomized Clinical Studies to Advance AB928, a Dual Adenosine Receptor Antagonist, into Novel Combinations for Colorectal and Pancreatic Cancers 4.9%
10/30 Form 4 Arcus Biosciences, Inc. For: Oct 28 Filed by: Ribas Antoni 4.5%
7/4 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.25 price target on the stock. 4.4%
2/18 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. 12.7%
8/8 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 11.0%
3/4 Arcus Biosciences Inc (NYSE: RCUS) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $24.00 price target on the stock. 7.7%
6/11 Arcus Biosciences to Provide a Mid-Year Update on Clinical and Preclinical Programs 6.4%
11/12 Arcus Biosciences Inc (NYSE: RCUS) is now covered by analysts at SunTrust Banks, Inc.. They set a "buy" rating on the stock. 5.4%
4/9 Arcus Biosciences Announces New Employment Inducement Grants 5.3%
12/18 Arcus Biosciences, in Collaboration with Genentech, Announces Two Randomized Clinical Studies to Advance AB928, a Dual Adenosine Receptor Antagonist, into Novel Combinations for Colorectal and Pancreatic Cancers 4.9%
10/30 Form 4 Arcus Biosciences, Inc. For: Oct 28 Filed by: Ribas Antoni 4.5%
7/4 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.25 price target on the stock. 4.4%
TOP News Decliners
3/14
Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock.
-24.3%
2/25 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.5%
11/25 Form 8-K/A Arcus Biosciences, Inc. For: Sep 10 -8.8%
4/7 Form 8-K Arcus Biosciences, Inc. For: Apr 07 -7.6%
11/7 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.3%
10/4 Form 3 Arcus Biosciences, Inc. For: Oct 01 Filed by: Barker Jason -6.7%
4/16 Arcus stock jumps on Bloomberg News report that Gilead may take a stake [MarketWatch] -6.3%
3/3 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. -5.3%
2/22 3 Biotech Stocks That Soared This Week: Are They Buys? [The Motley Fool] -5.1%
2/26 Arcus Biosciences Inc (NYSE: RCUS) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $22.00 price target on the stock. -4.8%
2/25 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.5%
11/25 Form 8-K/A Arcus Biosciences, Inc. For: Sep 10 -8.8%
4/7 Form 8-K Arcus Biosciences, Inc. For: Apr 07 -7.6%
11/7 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.3%
10/4 Form 3 Arcus Biosciences, Inc. For: Oct 01 Filed by: Barker Jason -6.7%
4/16 Arcus stock jumps on Bloomberg News report that Gilead may take a stake [MarketWatch] -6.3%
3/3 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. -5.3%
2/22 3 Biotech Stocks That Soared This Week: Are They Buys? [The Motley Fool] -5.1%
2/26 Arcus Biosciences Inc (NYSE: RCUS) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $22.00 price target on the stock. -4.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: